The product is licensed by clients such as aging-in-place facilities, wellness-focused businesses, care management organizations, health systems, and employee benefits leaders.
Enterprises can deploy the solution for use with a general managed population or an at-risk population, such as seniors, postoperative patients, those with health conditions, or new mothers.
Through an easy-to-use dashboard, an enterprise can survey, message and educate its population while the connected mobile App empowers and engages patients/employees and their families through alerts, journals, reminders, surveys, instant messaging, and tailored content.
Research by the American Heart Association indicates that incorporating family support and providing easy-to-read educational material to patients and their caregivers enhance medication adherence.
Another element of the App is targeted educational assistance (TEA), a health condition education content that is auto-delivered to the App from sources such as the National Library of Medicine.
The App also includes features to increase medication adherence. The dashboard also contains population health analytics tools tailored to the needs of the enterprise.
ICMed is a mobile patient & family engagement solution.
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents
Hansa Biopharma submits imlifidase Biologics License Application to FDA
T-MAXIMUM Pharmaceutical receives IND approval to start Phase II trial of MT027 for rGBM
Ipsen closes Phase II FALKON trial after missing primary endpoint in FOP
Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study